Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Adult-onset Still disease is a rare systemic autoinflammatory disorder characterized by recurrent high fever, arthritis, rash, and multi-organ inflammation. As per Global Autoimmune Institute, its prevalence ranges from 0.73 to 6.77 cases per 100,000 people worldwide. According to the adult onset still disease epidemiology forecast by Expert Market Research, increasing awareness and improved diagnosis are expected to support better disease recognition and management of systemic inflammation.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Adult Onset Still Disease – Number of Cases by Year

Read more about this report - Request a Free Sample

Adult Onset Still Disease Epidemiology Forecast Report Coverage

Expert Market Research's “Adult Onset Still Disease Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of adult onset still disease. It projects the future incidence and prevalence rates of adult onset still disease cases across various populations. The study covers age, gender, and type as major determinants of the adult onset still disease population. The report highlights patterns in the prevalence of adult onset still disease over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of adult onset still disease in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Adult Onset Still Disease Understanding: Disease Overview

Adult onset still disease (AOSD) is a rare systemic autoinflammatory disorder characterized by recurrent high fever, inflammatory arthritis, an evanescent salmon-colored rash, and elevated inflammatory markers. Although its exact cause remains unknown, the disease is believed to result from abnormal activation of the innate immune system, leading to excessive production of pro-inflammatory cytokines. Adult onset still disease is generally classified into three clinical patterns: monocyclic (single episode), polycyclic (recurrent flares), and chronic articular disease. Early recognition and systemic inflammation assessment are essential to minimize complications and improve long-term outcomes.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Region

India

High-Risk Population

Young adults, particularly individuals aged 16–35 years, with a slight female predominance

Key Diagnostic Method

Clinical evaluation supported by Yamaguchi or Fautrel classification criteria, inflammatory biomarkers, and exclusion of infectious, malignant, and autoimmune disorders

Major Risk Factor

Dysregulated immune response and excessive pro-inflammatory cytokine production

Major gap in the market

Delayed diagnosis due to nonspecific symptoms and the absence of disease-specific diagnostic biomarkers

Adult Onset Still Disease Epidemiology Perspective

The adult onset still disease epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the adult onset still disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for adult onset still disease and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

Adult-onset Still disease (AOSD) is a rare inflammatory disorder with an estimated global prevalence of 0.73–6.77 cases per 100,000 people. As per the Global Autoimmune Institute, improved awareness and diagnosis suggest the disease may be more frequently recognized than previously reported. Based on Sheng Li et al. (2023), another epidemiological estimate reported a prevalence of 3.9 cases per 100,000 individuals.

Gender-Specific Cases of the Disease

A slight female predominance has been observed in Adult-onset Still disease. According to the Global Autoimmune Institute, females are affected slightly more often than males. As reported by Eleonore de Fritsch et al. (2023), 70.6% of evaluated patients were female, indicating a higher disease burden among women in the studied population.

Age-Specific Cases of the Disease

Adult-onset Still disease predominantly affects young adults but may occur throughout adulthood. As per Christopher Saleh (2025), the disease demonstrates bimodal age peaks at 15–25 years and 36–46 years. Findings from Sushmita Mittal et al. (2024) similarly identified peaks at 15–25 years and 36–45 years, with increasing recognition among older adults.

Ethnicity-Wise Cases of the Disease

Disease burden may vary across ethnic populations due to differences in genetic susceptibility, environmental exposure, and healthcare accessibility. As reported by Eleonore de Fritsch et al. (2023), epidemiological evaluation in the Afro-Caribbean population contributes to understanding ethnic variations and supports broader population-based disease surveillance.

Mortality and Survival Analysis of the Disease

Mortality is generally associated with severe systemic disease and disease-related complications. According to Eleonore de Fritsch et al. (2023), 11.76% of patients died during follow-up, while 9% developed hemophagocytic lymphohistiocytosis, including one fatal case, highlighting the importance of early disease management and long-term monitoring.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Systemic Pattern

As reported by Eleonore de Fritsch et al. (2023), the systemic pattern accounted for 78.8% of Adult-onset Still disease cases, representing the predominant clinical subtype and contributing substantially to the overall epidemiological burden.

Chronic Joint Pattern

The chronic joint pattern represents a recognized subtype characterized by persistent articular involvement and contributes to the long-term disease burden through ongoing disease activity and healthcare utilization.

Adult Onset Still Disease – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Adult Onset Still Disease Epidemiology

The adult onset still disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

Findings from Sushmita Mittal et al. (2024) indicate that Adult-onset Still disease has an estimated annual incidence of 0.16–0.40 cases per 100,000 adults in the United States and exhibits a bimodal age distribution with peaks at 15–25 years and 36–45 years.

Germany

Adult-onset Still disease is recognized as a rare inflammatory disorder in Germany, with epidemiological assessments focusing on disease occurrence, demographic distribution, and healthcare burden within the affected population.

France

Olfa Frikha et al. (2025) estimated the prevalence of Adult-onset Still disease in France at 0.16–0.40 cases per 100,000 people. Based on Sheng Li et al. (2023), a French survey also found that 18% of patients were older than 55 years at diagnosis, reflecting an increasing proportion of older-onset cases.

Italy

As per Sheng Li et al. (2023), 16.7% of Adult-onset Still disease patients in Italy experienced disease onset after 60 years of age, demonstrating the growing recognition of elderly-onset disease within the country.

Spain

Adult-onset Still disease remains an uncommon inflammatory disorder in Spain, where epidemiological evaluations generally focus on disease frequency, demographic characteristics, and healthcare burden across affected populations.

United Kingdom

The epidemiological studies in the United Kingdom primarily assess disease occurrence, demographic trends, and patterns of healthcare utilization among affected individuals.

Japan

According to Olfa Frikha et al. (2025), the estimated prevalence of Adult-onset Still disease in Japan is 3.7 cases per 100,000 people. As reported by Sheng Li et al. (2023), 33.1% of patients were older than 60 years in 2021, increasing to 41.9% older than 65 years in 2022, indicating a shift toward older age at disease onset.

India

Adult-onset Still disease is recognized as a rare inflammatory disorder in India, with epidemiological evaluations emphasizing disease recognition, demographic distribution, and patterns of diagnosis among affected adult populations.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The regional epidemiology landscape for Adult Onset Still Disease continues to face significant challenges because of limited disease awareness, delayed diagnosis, and the absence of validated disease-specific biomarkers. Many cases remain underrecognized, particularly in emerging healthcare systems, resulting in incomplete epidemiological data and delayed treatment initiation. Increasing physician awareness, expanding access to advanced diagnostic testing, strengthening rare disease registries, and improving surveillance programs present substantial opportunities for more accurate disease burden estimation. Enhanced real-world evidence generation across the United States, Europe, Japan, and India will further support clinical decision-making and healthcare planning.

Adult Onset Still Disease: Treatment Overview

Treatment for adult onset still disease focuses on controlling inflammation, relieving symptoms, preventing disease progression, and reducing the risk of complications. Mild cases are commonly managed with nonsteroidal anti-inflammatory drugs and corticosteroids, while persistent or severe disease often requires conventional disease-modifying antirheumatic drugs, such as methotrexate. Patients with refractory or systemic manifestations may benefit from biologic therapies targeting interleukin-1 or interleukin-6 pathways, and, in selected cases, tumor necrosis factor inhibitors. Regular cytokine-targeted therapy monitoring and multidisciplinary care are essential to achieve sustained disease remission.

Key Questions Answered

  • What is the current and projected burden of adult onset still disease across the 8 major markets?
  • Which countries across the 8 major markets account for the highest adult onset still disease patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of adult onset still disease across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of adult onset still disease across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of adult onset still disease across the 8 major markets?
  • How do major comorbidities and risk factors influence adult onset still disease epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of adult onset still disease across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the adult onset still disease landscape across the 8 major markets?
  • Which therapeutic areas linked to adult onset still disease are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the adult onset still disease epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on adult onset still disease epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for adult onset still disease across the 8 major markets?

Scope of the Adult Onset Still Disease Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of adult onset still disease based on several factors.
  • Adult Onset Still Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The adult onset still disease report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Psoriatic Arthritis Pipeline Analysis Report

Rheumatoid Arthritis Therapeutics Market

Psoriatic Arthritis Treatment Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us